1. Genc H, Dogru T, Tapan S ve ark. Soluble CD40 ligand, soluble P-selectin and von Willebrand factor levels in subjects with prediabetes: The impact of metabolic syndrome. Clin Biochem. 2012 Jan;45(1-2):92-5.
2. Genc H, Dogru T, Tapan S ve ark. Circulating vaspin and its relationship with insulin sensitivity, adiponectin, and liver histology in subjects with non-alcoholic steatohepatitis. Scand J Gastroenterol. 2011;46(11):1355-61.
3. Sonmez A, Haymana C, Tapan S, Safer U, Celebi G, Ozturk O, Genc H, ve ark. Chitotriosidase activity predicts endothelial dysfunction in type-2 diabetes mellitus. Endocrine. 2010;37(3):455-9.
4. Kilciler G, Genc H, Tapan S, ve ark. Mean platelet volume and its relationship with carotid atherosclerosis in subjects with non-alcoholic fatty liver disease. Ups J Med Sci. 2010;115(4):253-9.
5. Tapan S, Dogru T, Kara M, Ercin CN, Kilciler G, Genc H, ve ark. Circulating levels of interleukin-18 in patients with non-alcoholic fatty liver disease. Scand J Clin Lab Invest. 2010;70(6):399-403.
6. Sonmez A, Celebi G, Erdem G, Tapan S, Genc H ve ark. Plasma apelin and ADMA Levels in patients with essential hypertension. Clin Exp Hypertens. 2010;32(3):179-83.
7. Tasci I, Erdem G, Ozgur G, Tapan S, Dogru T, Genc H, ve ark. LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. Atherosclerosis. 2009;204(1):222-
8. Erdem G, Genç H, Tapan S, ve ark. Circulating von Willebrand factor levels in patients with prediabetes. Turkish J Med Sci 2008;28(6):822-27.
9. Dogru T, Genc H, Tasci I, ve ark. Platelet aggregation is not enhanced in patients with prediabetes. Ups J Med Sci. 2007;112(3):338-46.
10. Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H ve ark. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract. 2007;76(1):24-9.
11. Tasci I, Dogru T, Sonmez A, Genc H ve ark. Soluble CD40 ligand levels in otherwise healthy subjects with impaired fasting glucose. Mediators Inflamm. 2006;2006(5):32508.
12. Dogru T, Tasci I, Sonmez A, Genc H, ve ark. The plasma levels of soluble P-selectin in subjects with prediabetes. Int J Clin Pract. 2006;60(9):1048-52.
13. Dogru T, Genc H, Tapan S,. Hyperuricemia in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;34(8):1042-3
14. Dogru T, Genc H, Ercin CN, Tapan S. Non-invasive prediction of fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2011;55(2):498-9.
15. Dogru T, Genc H, Kara M, Karadurmus N. Microalbuminuria and nonalcoholic fatty liver disease. Metabolism. 2010;59(9):E5
16. Dogru T, Karadurmus N, Tapan S, Genc H. Comment and reply on: Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2010;45(7-8):1000-1.
17. Genc H, Karadurmus N, Kisa U ve ark. T. Transforming growth factor β (TGF-β) levels in otherwise healthy subjects with impaired glucose tolerance. Endokrynol Pol. 2010;61(6):691-4.
18. Dogru T, Sonmez A, Tasci I, Genc H. Symptomatic hypocalcemia due to oral risedronate therapy. Ind. J. Med. Sci 2005;59:542-543
19. Sonmez A, Nikolic D, Dogru T, Ercin CN, Genc H, Cesur M, Tapan S, Karslioglu Y, Montalto G, Banach M, Toth P, Rizzo M. Low- and high-density lipoprotein subclasses in subjects with non-alcoholic fatty liver disease. J Clin Lipidol. 2015 Jul-Aug;9(4):576-582.
20. Celebi G, Genc H, Gurel H, ve ark. The relationship of circulating fetuin-a with liver histology and biomarkers of systemic inflammation in nondiabetic subjects with nonalcoholic fatty liver disease. Saudi J Gastroenterol. 2015 May-Jun;21(3):139-45.
21. Sertoglu E, Ercin CN, Celebi G, Gurel H, Kayadibi H, Genc H, ve ark. The relationship of serum uric acid with non-alcoholic fatty liver disease. Clin Biochem. 2014
22. Kara M, Genc H, Tapan S, ve ark. Alpha fetoprotein levels and its relationship with histopathological findings in patients with non-alcoholic fatty liver disease. Eur Rev Med Pharmacol Sci. 2013 Jun;17(11):1536-41.
23. Gurel H, Genc H, Celebi G ve ark. Plasma pentraxin-3 is associated with endothelial dysfunction in non-alcoholic fatty liver disease. Eur Rev Med Pharmacol Sci. 2016 Oct;20(20):4305-4312.
